Aquestive Therapeutics granted Eton Pharmaceuticals exclusive U.S. commercialization rights to LIBERVANT (diazepam) buccal film for the acute treatment of seizure clusters, receiving a $10 million upfront license fee. The agreement includes potential regulatory and commercial milestone payments totaling up to $47.5 million and mid-teens percentage royalties on net sales. Aquestive will serve as the exclusive manufacturer under a 20-year supply agreement. Eton anticipates a commercial launch in April 2027, subject to final FDA approval for patients aged 12 and older, with an additional application pending for ages 6-11. Aquestive Therapeutics is a pharmaceutical company advancing medicines through innovative science and delivery technologies.
